Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene

European Journal of Endocrinology

Volumn 158, Issue 3, 2008, Pages 417-422

  Foppiani, Luca ^a,d   Forzano, F ^a   Ceccherini, I ^b   Bruno, W ^c   Ghiorzo, P ^c   Caroli, F ^b   Quilici, P ^a   Bandelloni, R ^a   Arlandini, A ^a   Sartini, G ^a   Cabria, M ^a   Del Monte, P ^a  

^a GALLIERA HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d S S D Endocrinologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CREATINE KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PARATHYROID HORMONE; PENTAGASTRIN; PROTEIN RET; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; CELL HYPERPLASIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; EXON; FAMILY HISTORY; GENE MUTATION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; HUMAN TISSUE; HYPERCALCITONINEMIA; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MISSENSE MUTATION; MULTIPLE ENDOCRINE NEOPLASIA; NEOPLASM; PANCREAS CANCER; PARATHYROID ADENOMA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SIPPLE SYNDROME; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADENOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION, MISSENSE; PARATHYROID NEOPLASMS; PEDIGREE; PROTO-ONCOGENE PROTEINS C-RET;

EID: 40949125553     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0608     Document Type: Article

References (41)

1. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M & Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2007 92 450-455.
2. Brandi ML, Gagel RF, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C, Cont-Devolx B, Falchetti A, Gionata Gheri R, Libraia A, Lips CJM, Lombardi G, Mannelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells S Jr & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671.
3. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE & Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Archives of Surgery 2003 138 409-416.
4. Fugazzola L, Cerutti N, Mannavola D, Ghilardi G, Alberti L, Romoli R & Beck-Peccoz P. Multigenerational familial medullary throid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clinical Endocrinology 2002 56 53-63.
5. Santoro M, Melillo RM, Carlomagno F, Vecchio G & Fusco A. Minireview RET: normal and abnormal functions. Endocrinology 2004 145 5448-5451.
6. Guyetant S, Blechet C & Saint-Andre JP. C-cell hyperplasia. Annales d'Endocrinologie 2006 67 190-197.
7. Borget I, De Pourville G & Schlumberger M. Editorial: calcitonin determination in patients with nodular thyroid disease. Journal of Clinical Endocrinology and Metabolism 2007 92 425-427.
8. Verga U, Ferrero S, Vicentini L, Brambilla T, Cirelio, V, Muzza M, Beck-Peccoz P & Fugazzola L. Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocrine-Related Cancer 2007 14 393-403.
9. Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B & Guerin O. Sex-related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. Journal of Clinical Endocrinology and Metabolism 1997 82 42-47.
10. Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K, Bieglmayer C, Niederle B, Dudczak R & Pirich C. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2004 89 515-519.
11. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A & Pacini F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. Journal of Clinical Endocrinology and Metabolism 2004 89 163-168.
12. Papaparaskeva K, Nagel H & Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagnostic Cytopathology 2000 22 351-358.
13. Chang TC, Wu SL & Hsiao YL. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytologica 2005 49 477-482.
14. Sena de la Saravia C, Cuellar F, Saravio Day E & Harach HR. Accuracy of aspiration cytology in thyroid cancer: a study in one institution. Acta Cytologica 2006 50 384-387.
15. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Human Mutation 2004 23 630.
16. Schuetz M, Beheshti M, Oczer S, Novotny C, Paul M, Hofmann A, Bieglmayer C, Niederle B, Kletter K, Dudczak R, Karanikas G & Pirich C. Calcitonin measurements for early detection of medullary thyroid carcinoma or its premalignant conditions in Hashimoto's thyroiditis. Anticancer Research 2006 26 723-728.
17. Rone JK, Lane AG & Grinkemeyer MD. Papillary thyroid carcinoma, parathyroid adenoma, and unexplained hypercalcitoninemia: an unusual presentation of multiple endocrine neoplasia typ2 2A? Thyroid 1998 8 781-785.
18. Sancandi M, Ceccherini I, Costa M, Fava M, Chen B, Wu Y, Hofstra R, Laurie T, Griffiths M, Burge D & Tam PK. Incidence of RET mutations in Hirschsprung's disease patients. Journal of Pediatric Surgery 2000 35 139-142.
19. Lantieri F, Griseri P, Puppo F, Campus R, Martucciello, G, Ravazzolo R, Devoto M & Ceccherini I. Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derive from a single ancestral combination of alleles. Annals of Human Genetics 2006 70 12-26.
20. Ghiorzo P, Gargiulo S, Pastorino L, Nasti S, Cusano R, Bruno W, Gliori S, Sertoli MR, Burroni A, Savarino V, Gensini F, Sestini R, Queirolo P, Goldstein AM & Scarra GB. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Human Molecular Genetics 2006 15 2682-2689.
21. Perry A, Molberg K & Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 1996 77 750-756.
22. Guyetant S, Josselin N, Savagner F, Rohmer V, Michalak S & Saint-André JP. C-cell, hyperplasia and medullary thryoid carcinoma, clinicopathological and genetic correlations in 66 consecutive patients. Modern Pathologyy 2003 16 756-763.
23. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R & Wolfe HJ. Germline RET634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. Journal of Clinical Endocrinology and Metabolism 2001 86 3948-3957.
24. Saggiorato E, Rapa I, Garino F, Bussolati G, Orlandi F, Papotti MN & Volante M. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia. Journal of Molecular Diagnostics 2007 9 214-219.
25. Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J & Ponder BA. Germline homozygous mutations at codon 804 in the RET proto-oncogene in medullary thyroid carcinoma/ multiple endocrine neoplasia type 2A patients. Journal of Clinical Endocrinology and Metabolism 2005 90 3454-3457.
26. Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV & Robinson BG. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clinical Endocrinology 2005 63 636-641.
27. Frohnauer MK & Decker PA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000 128 1052-1058.
28. Recasens M, Oriola J, Fernddnez-Real JM, Roig J, Rodriguez-Hermosa JI, Font JA, Galofre P, López-Bermejo A & Ricart W. Asymptomatic bilateral adrenal pheocromocytorna in a patient with a germline V804M mutation in the RET protooncogene. Clinical Endocrinology 2007 67 29-33.
29. Cebrian A, Lesueue F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM & Ponder BA. Polymorphisms in the initiators of RET (rearranged during transfection) signalling pathway and susceptibility to sporadic medullary thryoid carcinoma. Journal of Clinical Endocrinology and Metabolism 2005 90 6268-6274.
30. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F & Pinchera A. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. Journal of Clinical Endocrinology and Metabolism 2005 89 3579-3584.
31. Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhausl W & Vierhaper H. Polymorphisms in exon 13 and intron 14 of the RET proto-oncogene: genetic modifiers of medullary carcinoma? Journal of Clinical Endocrinology and Metabolism 2005 90 6232-6236.
32. Gursoy A, Erdogan MF & Erdogan G. Significance of the RET protooncogene polymorphism in Turkish sporadic medullary thyroid carcinoma patients. Journal of Endocrinological Investigation 2006 29 858-862.
33. Lesucur E Cebrian A, Robeldo M, Niccoli-Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah P & Ponder BAJ. Polymorphism in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Research 2006 66 1177-1180.
34. Costa P, Domingues R, Sobrinho LG & Bugalho MJ. RET polymorphism and a sporadic medullary thyroid carcinoma in a Portuguese population. Endocrine 2005 27 239-243.
35. Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G & Pierotti MA. CDKN2A and CDK4 mutation analysis in Italian mclanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. British Journal of Cancer 2001 85 836-844.
36. Mantelli M, Pastorino L, Ghiorzo P, Barile M, Bruno W, Gargiulo S, Sormani MP, Gliori S, Vecchio S, Ciotti P, Sertoli MR, Queirolo P, Goldstein AM, Bianchi-Scarra G & Italian Melanoma Intergroup. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Research 2004 14 443-448.
37. Huber J & Ramos ES. The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Brazilian Journal of Medical and Biological Research 2006 39 237-241.
38. Szell M, Balogh K, Bobozy A, Kemeny L & Olah J. First detection of the melanoma-predisposing praline-48-threonine mutation of p 16 in Hungarians: was there a common founder either in Italy or in Hungary? Melanoma Research 2007 17 251-254.
39. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MV, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais E Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RE Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille 1A, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E & Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Research 2006 66 9818-9828.
40. Moore PS, Zamboni G, Falconi M, Bassi C & Scarpa A. A novel germline mutation, P48T, in the CDKN2A/p16 gene in a patient with pancreatic carcinoma. Human Mutation 2000 16 447-448.
41. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA Jr & Godfellow PJ. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Molecular Carcinogenesis 1996 15 5-10.